Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis

NCT00003704 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00003704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 1
Overall status
Completed
Start date
April 30, 1999
Completion date
July 31, 2003
Enrollment
51 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

cancer